Serhiyenko V A
Danylo Halytsky National Medical University, Lviv, Ukraine.
Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(1):80-84. doi: 10.17116/jnevro20151151180-84.
To analyze the effect of long-chain (LC) polyunsaturated w-3 fatty acids (PUFAs) on the daily arterial stiffness parameters in patients with type 2 diabetes (DM2) and cardiovascular autonomic neuropathy (CAN).
The study involved 39 patients with DM2 and verified functional stage of CAN. Patients were divided into 2 groups: therapy group (n=21) and control group (n=18). Patients of the control group received traditional hypoglycemic therapy; patients of the therapy group additionally received 1 capsule/day of the ω-3 PUFAs for three months.
The use of the ω-3 PUFAs resulted in a statistically significant decrease in aortic augmentation index (AAI) and pulse wave velocity in the aorta (PWV) during the active period. There was a decrease in AAI in the aorta and the brachial artery and in PWV in the aorta during the night.
The efficacy of ω-3-PUFAs is a result of a direct effect of the pharmacological agent on the circadian arterial stiffness parameters.
分析长链（LC）多不饱和ω-3脂肪酸（PUFAs）对2型糖尿病（DM2）合并心血管自主神经病变（CAN）患者每日动脉僵硬度参数的影响。
本研究纳入39例确诊为DM2且处于CAN功能阶段的患者。患者被分为2组：治疗组（n = 21）和对照组（n = 18）。对照组患者接受传统降糖治疗；治疗组患者额外每日服用1粒ω-3 PUFAs，持续三个月。
在治疗期，使用ω-3 PUFAs导致主动脉增强指数（AAI）和主动脉脉搏波速度（PWV）在统计学上显著降低。夜间，主动脉和肱动脉的AAI以及主动脉的PWV均有所下降。
ω-3-PUFAs的疗效是该药物对昼夜动脉僵硬度参数直接作用的结果。
